Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Iscaff Pharma AB is currently prosecuting patent applications in the Biotechnology & Pharmaceuticals technology area. The portfolio data reveals 1 pending office action. This matter is handled by 1 distinct examiner. The prosecution is also limited to 1 distinct art unit. This indicates a very focused legal landscape where the company's current filings are reviewed by a single official in a single technical department.
The busiest examiner for the company is HOPKINS, SAMANTHA LAKE, who holds 1 pending office action. This count is identical to the 1 total pending office action for the portfolio. Practitioners should focus their efforts on the specific preferences of HOPKINS, SAMANTHA LAKE. Because the number of distinct examiners is 1 and the number of distinct art units is 1, there is no diversity in the current review process. The 1 pending action represents the entire active workload, making the interaction with HOPKINS, SAMANTHA LAKE critical for the portfolio's success.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOPKINS, SAMANTHA LAKE | 1 | 60.7% | +61.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18387292 | DIAGNOSTIC METHODS | HOPKINS, SAMANTHA LAKE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18387292 | DIAGNOSTIC METHODS | HOPKINS, SAMANTHA LAKE | — |
| Art Unit | Apps |
|---|---|
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18387292 | DIAGNOSTIC METHODS | HOPKINS, SAMANTHA LAKE | 1677 | §101§103§112Other | Non-Final OA | — | Pending | Nov 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIscaff Pharma AB has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Samantha Lake Hopkins has the most, with 1 of Iscaff Pharma AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
